Regeneron halting higher doses in fasinumab trials

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab. Regeneron will modify ongoing trials to continue with two lower doses, President and CSO George Yancopoulos said on a conference call on May 3.

Regeneron said recommendations were based on a risk-benefit analysis, but declined to disclose details about the higher doses or whether the analysis was planned...